EA200971013A1 - Соединения-антагонисты рнк для модуляции активности бета-катенина - Google Patents

Соединения-антагонисты рнк для модуляции активности бета-катенина

Info

Publication number
EA200971013A1
EA200971013A1 EA200971013A EA200971013A EA200971013A1 EA 200971013 A1 EA200971013 A1 EA 200971013A1 EA 200971013 A EA200971013 A EA 200971013A EA 200971013 A EA200971013 A EA 200971013A EA 200971013 A1 EA200971013 A1 EA 200971013A1
Authority
EA
Eurasian Patent Office
Prior art keywords
beta
modulation
oligomers
antagonist compounds
beta catenin
Prior art date
Application number
EA200971013A
Other languages
English (en)
Other versions
EA018986B1 (ru
Inventor
Йеспер Ворм
Original Assignee
Сантарис Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантарис Фарма А/С filed Critical Сантарис Фарма А/С
Publication of EA200971013A1 publication Critical patent/EA200971013A1/ru
Publication of EA018986B1 publication Critical patent/EA018986B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к олигомерным соединениям (олигомерам), мишенью которых в клетке является мРНК бета-катенина и которые вызывают уменьшение экспрессии бета-катенина. Уменьшение экспрессии бета-катенина является полезным при ряде медицинских нарушений, таких как гиперпролиферативные заболевания, включая рак. Изобретение предоставляет терапевтические композиции, включающие в себя олигомеры, и методы модулирования экспрессии бета-катенина с применением указанных олигомеров, включая методы лечения.
EA200971013A 2007-05-01 2008-04-30 Соединения-антагонисты рнк для модуляции активности бета-катенина EA018986B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91537107P 2007-05-01 2007-05-01
US2324408P 2008-01-24 2008-01-24
PCT/EP2008/055365 WO2008132234A2 (en) 2007-05-01 2008-04-30 Rna antagonist compounds for the modulation of beta-catenin

Publications (2)

Publication Number Publication Date
EA200971013A1 true EA200971013A1 (ru) 2010-04-30
EA018986B1 EA018986B1 (ru) 2013-12-30

Family

ID=39926160

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971013A EA018986B1 (ru) 2007-05-01 2008-04-30 Соединения-антагонисты рнк для модуляции активности бета-катенина

Country Status (15)

Country Link
US (4) US20090005335A1 (ru)
EP (1) EP2152879B1 (ru)
JP (2) JP2010524486A (ru)
KR (1) KR20100024399A (ru)
CN (1) CN101842483A (ru)
AU (1) AU2008244211B2 (ru)
CA (1) CA2685444A1 (ru)
DK (1) DK2152879T3 (ru)
EA (1) EA018986B1 (ru)
ES (1) ES2399371T3 (ru)
IL (1) IL201865A0 (ru)
MX (1) MX2009011878A (ru)
NZ (1) NZ581200A (ru)
TW (1) TW200848077A (ru)
WO (1) WO2008132234A2 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008244211B2 (en) * 2007-05-01 2014-08-21 Santaris Pharma A/S RNA antagonist compounds for the modulation of beta-catenin
TW201102073A (en) 2009-07-15 2011-01-16 Enzon Pharmaceuticals Inc RNA antagonists targeting GLI2 for the treatment of leukemia
EP2591105B1 (en) 2010-07-06 2017-05-31 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
CN104093839A (zh) * 2011-11-11 2014-10-08 桑塔里斯制药公司 用于调节β-连环蛋白表达的化合物及其应用
CN104302768A (zh) * 2012-01-09 2015-01-21 诺华股份有限公司 治疗β-联蛋白相关疾病的有机组合物
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
EP3511416A1 (en) 2012-05-16 2019-07-17 Translate Bio MA, Inc. Compositions and methods for modulating gene expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
CA2893801A1 (en) * 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
WO2014179446A2 (en) 2013-05-01 2014-11-06 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-122
AU2014259953B2 (en) 2013-05-01 2020-07-02 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
KR101800981B1 (ko) 2013-08-22 2017-11-23 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 투사 컴퓨팅 시스템
TWI657755B (zh) * 2013-12-30 2019-05-01 Philip Morris Products S. A. 包含隔熱可燃熱源之煙品
AU2015212341A1 (en) 2014-02-03 2016-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of Casein kinase I inhibitors for depleting stem cells
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
EP3271460A4 (en) 2015-03-17 2019-03-13 The General Hospital Corporation INTERACTOME RNA OF COMPLEX REPRESSIVE POLYCOMB 1 (PRC1)
US11643655B2 (en) * 2016-11-15 2023-05-09 City Of Hope Methods for intracellular delivery and enhanced gene targeting

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
US6066500A (en) 1999-06-25 2000-05-23 Isis Pharmaceuticals Inc. Antisense modulation of Beta catenin expression
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US20030064384A1 (en) * 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
US20030143586A1 (en) * 2001-10-12 2003-07-31 Qimin Chao Genetic hypermutability of plants for gene discovery and diagnosis
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP1560931B1 (en) * 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
EP2141233B1 (en) 2002-11-18 2016-10-19 Roche Innovation Center Copenhagen A/S Antisense design
AU2004230927B9 (en) 2003-04-13 2011-12-01 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
US20050136395A1 (en) * 2003-05-08 2005-06-23 Affymetrix, Inc Methods for genetic analysis of SARS virus
US20070009899A1 (en) * 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
KR20080068019A (ko) 2005-09-15 2008-07-22 산타리스 팔마 에이/에스 아포지단백질-ｂ100 발현 억제용 ｒｎａ 길항제 화합물
JP5731115B2 (ja) 2006-05-05 2015-06-10 アイシス ファーマシューティカルズ， インコーポレーテッド 遺伝子発現を調節するための化合物および方法
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
EP2076257A4 (en) 2006-09-15 2014-04-16 Belrose Pharma Inc POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS
CN101554074B (zh) 2006-10-30 2012-08-22 诺基亚公司 为用户设备提供运营商控制的移动性的方法、设备和系统
AU2008244211B2 (en) 2007-05-01 2014-08-21 Santaris Pharma A/S RNA antagonist compounds for the modulation of beta-catenin

Also Published As

Publication number Publication date
JP2014209915A (ja) 2014-11-13
EP2152879B1 (en) 2012-11-14
TW200848077A (en) 2008-12-16
EP2152879A2 (en) 2010-02-17
AU2008244211B2 (en) 2014-08-21
US20120004288A1 (en) 2012-01-05
JP2010524486A (ja) 2010-07-22
KR20100024399A (ko) 2010-03-05
CA2685444A1 (en) 2008-11-06
WO2008132234A4 (en) 2009-07-09
US20090203137A1 (en) 2009-08-13
WO2008132234A2 (en) 2008-11-06
EA018986B1 (ru) 2013-12-30
US20110086902A1 (en) 2011-04-14
AU2008244211A1 (en) 2008-11-06
CN101842483A (zh) 2010-09-22
US7915401B2 (en) 2011-03-29
WO2008132234A3 (en) 2009-05-07
US8039446B2 (en) 2011-10-18
NZ581200A (en) 2012-04-27
ES2399371T3 (es) 2013-03-27
MX2009011878A (es) 2010-01-25
IL201865A0 (en) 2011-08-01
US20090005335A1 (en) 2009-01-01
DK2152879T3 (da) 2013-02-18

Similar Documents

Publication Publication Date Title
EA200971013A1 (ru) Соединения-антагонисты рнк для модуляции активности бета-катенина
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
EA201391639A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
EA201391532A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201071100A1 (ru) Пиридилсодержащие ингибиторы передачи сигнала через белок hedgehog
EA201490696A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
EA201690899A1 (ru) Оксазепины в качестве модуляторов ионных каналов
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA201291073A1 (ru) Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201391019A1 (ru) Соединения и способы для модуляции киназ, а также показания к их применению
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
MX2009004060A (es) Moduladores de proteina cinasa de triazolpiridazina.
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201291272A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU